The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Zacks.com on MSN1mon
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple MyelomaFollowing this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback